Key person interview

Words of co-creation, words of symbiosis
Collection of key person interviews

We will tell you about people's passion for drug discovery.

Deliver new drugs to Underserved Therapeutic Areas. To that end, SymBio Pharmaceuticals' activities are supported not only by our employees, but also by many other people. We interviewed key people inside and outside the company about episodes of new drug development, past and future business prospects, and expectations for SymBio Pharmaceuticals. The passion of people spread around drug discovery. Please listen to the words that are born from there.

The "Key Person Interview Collection" is included to provide our stakeholders with information related to our company. Although it may contain information on ethical drugs and development products, it is intended to provide information to the press, shareholders, and investors, and is intended for promotion, advertising, medical advice, etc. It is not intended to be

■Dear Experts

• 
  NEW
  The presentation at the ASH meeting in 2023 has
  reignited incredible enthusiasm about this drug to 
  treat Adenovirus.
  Medical Director, Bone Marrow Transplant and Immune Deficiency 
  Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center　　　　　　　　　　　　　Cincinnati, OH USA   
  Michael Grimley, MD Professor of Pediatrics
• 
  Resistance to viral infections after hematopoietic stem cell transplantation
  I want to support the development of new medicines in Japan.
  Fujita Health University
  Professor, Department of Hematopoietic Cell Transplantation and Cellular Therapy
  Professor Masahiro Inamoto
• 
  for EB virus-positive lymphoma,
  Expectations for the development of new treatments
  Department of Internal Medicine, Shimane University School of Medicine
  Hematology and Oncology Professor
  Mr. Ritsuro Suzuki
• 
  The possibility of treatment with a combination of drugs
  I want to expand through joint research
  Professor Emeritus, University of Tokyo
  Head of Advanced Medical Research Center, Kobe Medical Industry Development Organization
  University of Tokyo Faculty of Pharmaceutical Sciences Molecular Oncology Specially Appointed Researcher
  Professor Toshio Kitamura
• 
  Treatment options for relapsed or refractory DLBCL
  I am very happy to have increased
  Dokkyo Medical University Saitama Medical Center
  Department of Diabetes Endocrinology and Hematology Associate Professor
  Professor Toru Kiguchi
• 
  Save patients with excellent antiviral activity,
  Expectations for development of brincidofovir injection
  Memorial Sloan Kettering Cancer Center
  Infectious disease department doctor
  Weill Cornell Medical School Professor
  Dr. Genoveva Papanicola
• 
  overcoming development risks and financial crises
  I would like to express my utmost respect for achieving profitability.
  JAFCO Investment (Asia Pacific) Ltd
  President & CEO
  Yoshiyuki Shibusawa
• 
  Embracing a clear growth story,
  desire to work hard together
  Chairman of Well Investment Co., Ltd.
  Waseda University Professor Emeritus, Doctor of Commerce
  Mr. Shuichi Matsuda

■ SymBio Pharmaceutical members

• 
  The diverse results obtained through joint research
  We hope to use this knowledge to advance clinical development
  CSO and Director of Translational Research
  Masaaki Hasama
• 
  Always identify Underserved Therapeutic Areas,
  Agile global development
  Corporate Officer, Chief Medical Officer
  Koji Fukushima
• 
  We want to reach as many patients as possible.
  With that in mind, we provide information on the web.
  Real-life
  Director of Marketing
  Kenji Kikuchi
• 
  Construction of distribution system for own sales,
  And to achieve stable supply
  General Manager of Distribution Strategy Department
  Susumu Umehara